Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PDE8B | O95263 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1427736 | 1.00 | HSD17B10 (0.46) | HSD17B10ATMSMN1; SMN2PDE8BALDH1A1 | |
| SCHEMBL1061613 | 1.00 | HSD17B10 (0.46) | HSD17B10ATMSMN1; SMN2PDE8BALDH1A1 | |
| SCHEMBL23015233 | 0.95 | PDE8B (0.47) | HSD17B10ATMSMN1; SMN2PDE8BALDH1A1 | |
| SCHEMBL1009587 | 0.95 | PDE8B (0.47) | HSD17B10ATMSMN1; SMN2PDE8BALDH1A1 | |
| SCHEMBL31037649 | 0.95 | PDE8B (0.47) | HSD17B10ATMSMN1; SMN2PDE8BALDH1A1 | |
| SCHEMBL3815408 | 0.91 | ATM (0.44) | HSD17B10ATMSMN1; SMN2PDE8BALDH1A1 | |
| SCHEMBL6345733 | 0.91 | ATM (0.44) | HSD17B10ATMSMN1; SMN2PDE8BALDH1A1 | |
| SCHEMBL7923096 | 0.91 | ATM (0.42) | HSD17B10ATMSMN1; SMN2PDE8BALDH1A1 | |
| SCHEMBL31420888 | 0.91 | ATM (0.42) | HSD17B10ATMSMN1; SMN2PDE8BALDH1A1 | |
| SCHEMBL4574708 | 0.91 | ATM (0.42) | HSD17B10ATMSMN1; SMN2PDE8BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2025064718-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20250034200-A1 | Prodrugs of Neurosteroid Analogs and Uses Thereof | UNIV EMORY (US) | 2025-01-30 | — | — | US | disclosed |
| CN-115894447-B | METTL3 inhibitors and uses thereof | 成都先导药物开发股份有限公司 | 2024-10-01 | — | — | CN | disclosed |
| WO-2023086438-A1 | PRODRUGS OF NEUROSTEROID ANALOGS AND USES THEREOF | EMORY UNIVERSITY (US) | 2023-05-19 | — | — | WO | disclosed |
| CN-115894447-A | METTL3 inhibitors and uses thereof | 成都先导药物开发股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-3045206-B2 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV HEALTHCARE CO (US) | 2023-02-15 | — | — | EP | disclosed |
| US-20220213121-A1 | SUBSTITUTED 1,2,3,3a,4,5,7,9,13,13a-DECAHYDROPYRIDO[1',2':4,5]PYRAZINO[1,2-a]PYRROLO[1,2-c]PYRIMIDINES HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2022-07-07 | — | — | US | disclosed |
| CN-114340616-A | Pyrazole and imidazole derivatives as orexin antagonists, compositions and methods | 海格生物科学有限责任公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-110204537-B | 1,2, 5-oxadiazole derivatives as inhibitors of indoleamine 2, 3-dioxygenase | 盛世泰科生物医药技术(苏州)有限公司 | 2021-10-08 | — | — | CN | disclosed |
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-09-27 | — | — | US | disclosed |
| US-7196078-B2 | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPOARTION (US) | 2007-03-27 | — | — | US | disclosed |
| US-6878736-B1 | Histamine H3 receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2005-04-12 | — | — | US | disclosed |
| US-6806279-B2 | FOR THERAPY OF AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS, MULTIPLE SCLEROSIS, UVEITIS, AND PSORIASIS, ALLOGRAFT REJECTION, AND GRAFT-VERSUS-HOST DISEASE | SUNESIS PHARMACEUTICALS, INC. | 2004-10-19 | — | — | US | disclosed |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | ABBOTT LABORATORIES | 2004-08-12 | — | — | US | disclosed |
| US-20030149049-A1 | Small-molecule inhibitors of interleukin-2 | SUNESIS PHARMACEUTICALS, INC. | 2003-08-07 | — | — | US | disclosed |
| WO-2003051797-A2 | SMALL-MOLECULE INHIBITORS OF INTERLEUKIN-2 | SUNESIS PHARMACEUTICALS, INC. (US) | 2003-06-26 | — | — | WO | disclosed |
| EP-1056733-A1 | HISTAMINE H3 RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999042458-A1 | HISTAMINE H3 RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 1999-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225270-A1 | Pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | HSD17B10 4224/4885ATM 457/4885SMN1; SMN2 2284/4885 |
| US-20220213121-A1 | SUBSTITUTED 1,2,3,3a,4,5,7,9,13,13a-DECAHYDROPYRIDO[1',2':4,5]PYRAZINO[1,2-a]PYRROLO[1,2-c]PYRIMIDINES HAVING HIV INTEGRASE INHIBITORY ACTIVITY | TYMP, TYMS, POLA1 | HSD17B10 2403/4885ATM 4740/4885SMN1; SMN2 3758/4885 |
| US-20040167128-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | HSD17B10 3758/4885ATM 2591/4885SMN1; SMN2 1949/4885 |
| US-20250034200-A1 | Prodrugs of Neurosteroid Analogs and Uses Thereof | CYP11B2, CYP11B1, CYP21A2 | HSD17B10 60/4885ATM 2713/4885SMN1; SMN2 708/4885 |
| US-20030149049-A1 | Small-molecule inhibitors of interleukin-2 | IL2, IL2RA, HLA-DRB1 | HSD17B10 2354/4885ATM 4790/4885SMN1; SMN2 3620/4885 |
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | HSD17B10 3549/4885ATM 835/4885SMN1; SMN2 1576/4885 |
| US-20040157836-A1 | Sulfonamides having antiangiogenic and anticancer activity | METAP2, METAP1, DNPEP | HSD17B10 3758/4885ATM 2591/4885SMN1; SMN2 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.